Virios Therapeutics (NASDAQ:VIRI) Stock Rating Lowered by HC Wainwright

HC Wainwright downgraded shares of Virios Therapeutics (NASDAQ:VIRIGet Rating) from a buy rating to a neutral rating in a report published on Tuesday morning, The Fly reports.

Virios Therapeutics Price Performance

Shares of VIRI opened at $0.49 on Tuesday. Virios Therapeutics has a one year low of $0.47 and a one year high of $9.11. The firm has a market capitalization of $4.08 million, a P/E ratio of -0.25 and a beta of 0.63. The business has a fifty day moving average of $6.70 and a 200 day moving average of $5.21.

Virios Therapeutics (NASDAQ:VIRIGet Rating) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.07. Analysts expect that Virios Therapeutics will post -1.9 EPS for the current fiscal year.

Institutional Trading of Virios Therapeutics

Large investors have recently modified their holdings of the company. State Street Corp bought a new stake in shares of Virios Therapeutics in the second quarter worth $45,000. Wiley BROS. Aintree Capital LLC bought a new stake in Virios Therapeutics during the second quarter valued at about $47,000. UBS Group AG grew its holdings in Virios Therapeutics by 528.3% during the first quarter. UBS Group AG now owns 14,137 shares of the company’s stock valued at $63,000 after purchasing an additional 11,887 shares during the period. Koshinski Asset Management Inc. bought a new stake in Virios Therapeutics during the second quarter valued at about $173,000. Finally, Cetera Advisors LLC grew its holdings in Virios Therapeutics by 22.0% during the first quarter. Cetera Advisors LLC now owns 43,944 shares of the company’s stock valued at $197,000 after purchasing an additional 7,934 shares during the period. Institutional investors own 13.63% of the company’s stock.

Virios Therapeutics Company Profile

(Get Rating)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Featured Stories

The Fly logo

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.